Effect of a Collagen Hydrolysate on Postprandial Blood Glucose Profile in Prediabetic and Healthy Subjects

Last updated: December 16, 2024
Sponsor: Rousselot BVBA
Overall Status: Completed

Phase

N/A

Condition

N/A

Treatment

Collagen hydrolysate

Placebo

Clinical Study ID

NCT05887791
BTS1984/23
  • Ages 18-70
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

To investigate the effect of two different dosages collagen hydrolysate (CH) on postprandial blood glucose and insulin profile in prediabetic and normo-glycaemic subjects.This will be investigated in a cross-over randomized double-blind placebo controlled study design.

Eligibility Criteria

Inclusion

Main Inclusion Criteria:

  • Prediabetic subjects: Male and female subjects with prediabetic HbA1c values between 5.7% and 6.4% and/or fasting glucose ≥ 100 mg/dL and ≤ 125 mg/dL (in venous plasma) (twice confirmed at two independent days if HbA1c is < 5.7%) or Healthynormo-glycaemic subjects: fasting glucose <100 mg/dL and HbA1c is < 5.7%

  • Age: 18-70 years

  • Body mass index 19-35 kg/m2

  • Current Non-smoker

  • Signed informed consent form

  • No changes in food habits or physical activity 3 months prior to screening andduring the study

  • If applicable, stable intake of chronic medication of at least 4 weeks

Exclusion

Main Exclusion Criteria:

  • Subjects with diagnosed Type 2 Diabetes mellitus with medical treatment

  • Presence of disease or drug(s) influencing digestion (incl. recent intake ofantibiotics) and absorption of nutrients

  • Intake of medications known to affect glucose tolerance, e.g., diabetic medication,SGLT-2 inhibitors, GLP-1 receptor agonists, steroids, protease inhibitors orantipsychotics

  • Chronic intake of substances affecting blood coagulation (e.g. acetylic acid (100 mgas standard prophylactic treatment allowed when dose is stable 1 month prior toscreening), anticoagulants, diuretics, thiazides (diuretics and thiazides allowede.g. for hypertension treatment when dose is stable 1 month prior to screening)),which in the Investigator's opinion would impact patient safety

  • Severe liver or renal disease or laboratory evidence of hepatic dysfunction (i.e.alkaline phosphatase, ALT, AST >3 x ULN)

  • Known inflammatory or malignant gastrointestinal diseases (i.e. colitis ulcerosa,Morbus Crohn, celiac disease, malignant diseases e.g. colon-cancer, rectum cancer,pancreatitis)

  • Clinically relevant findings as established by medical history, physicalexamination, clinical laboratory and/or vital signs

  • Intake of food supplements known to affect glucose tolerance, e.g., cinnamoncapsules, conjugated linoleic acids

  • Drug-, alcohol- and medication abuses

  • Pregnant or breast-feeding women

Study Design

Total Participants: 15
Treatment Group(s): 2
Primary Treatment: Collagen hydrolysate
Phase:
Study Start date:
June 15, 2023
Estimated Completion Date:
April 01, 2024

Connect with a study center

  • BioTeSys GmbH

    Esslingen, 73728
    Germany

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.